JP2013531023A - ビタミンdの14−エピ−アナログの新しい製剤 - Google Patents
ビタミンdの14−エピ−アナログの新しい製剤 Download PDFInfo
- Publication number
- JP2013531023A JP2013531023A JP2013519093A JP2013519093A JP2013531023A JP 2013531023 A JP2013531023 A JP 2013531023A JP 2013519093 A JP2013519093 A JP 2013519093A JP 2013519093 A JP2013519093 A JP 2013519093A JP 2013531023 A JP2013531023 A JP 2013531023A
- Authority
- JP
- Japan
- Prior art keywords
- vitamin
- epi
- formulation
- oral
- analog
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
Abstract
Description
-少なくとも一つのビタミンDの14-エピ-アナログ、
-カルボキシメチルセルロース(carboxymethylcellulose:CMC)
および、ひとつまたは複数の任意選択による医薬として許容可能な賦形剤。
-少なくとも一つのビタミンDの14-エピ-アナログ、
-少なくとも一つの長鎖トリグリセリド(LCT)、
および、ひとつまたは複数の任意選択による医薬として許容可能な賦形剤。
-少なくとも一つのビタミンDの14-エピ-アナログ、
-プロピレングリコール
および、ひとつまたは複数の任意選択による医薬として許容可能な賦形剤。
イネカルシトールは、ラッカセイ油、オリーブ油、ヒマワリ油(0.4mg/ml、すなわち0.044% w/w)、プロピレングリコール(0.4mg/ml、すなわち0.039% w/w)、オレイン酸(0.4mg/ml、すなわち0.045% w/w)、MCT(0.4mg/ml、すなわち0.042% w/w)もしくはCapmul PG8(登録商標) (0.4 mg/mlすなわち 0.044% w/w)に溶解、または、錠剤製剤(コーティングなしで重さ150mgの各錠剤中5mgのCMCおよび2mgのイネカルシトール)中での濃度3.33%(w/w)に対応する、0.5%(w/v)カルボキシメチルセルロースを含む医薬グレードの蒸留水中に細かい乳状懸濁液として分散させた。雄のカニクイザルに、各賦形剤について同じ体積(5ml/kg)での、高用量のイネカルシトール(2mg/kg)の単回経口投与を受けさせた。血液サンプルを、投与時、15分後、30分後、45分後、60分後、90分後、3時間後、6時間後、9時間後および24時間後に取り出した。血漿アリコートを、ヘパリン化されたチューブで調製し、未変化のイネカルシトールをHPLC/MS/MS法で特異的にアッセイした。薬物動態プロファイル(±SEM)の平均値を図1〜4にプロットする;平均最高濃度(Cmax)および投与後24時間の曲線の下の領域(AUC0-24h)は、イネカルシトールの参照MCT溶液で観察された平均値に関して、表した(表1); 同じ治療を受けた異なる動物でCmaxが観察された中央時間(Tmax)を決定した(表1)。
2mgイネカルシトール錠剤組成物
Claims (12)
- ビタミンDの14-エピ-アナログの中鎖トリグリセリド(MCT)製剤を上回って改良された吸収プロファイルによって特徴づけられる、前記ビタミンDの14-エピ-アナログの経口製剤。
- 中鎖トリグリセリド製剤を上回って、前記ビタミンDの14-エピ-アナログの吸収を改良するために使用するための、前記ビタミンDの14-エピ-アナログの経口製剤。
- 対応するMCT製剤よりも、高い最高濃度(Cmax)および任意に高い総合的な吸収(AUC0-24h)によって特徴づけられる、請求項1または2に記載の経口製剤。
- 前記製剤が以下を含む乾燥製剤である、請求項1から3のいずれか一項に記載の経口製剤:
-少なくとも一つのビタミンDの14-エピ-アナログ、
-カルボキシメチルセルロース(CMC)、および、
-ひとつまたは複数の任意選択による医薬として許容可能な賦形剤。 - CMCが濃度0.1〜50%(重量)で含まれる、請求項4に記載の経口製剤。
- 前記14-エピアナログがイネカルシトールである、請求項1から5のいずれか一項に記載の経口製剤。
- 前記ビタミンDの14-エピ-アナログが、濃度0.001〜50%(重量)で含まれる、請求項1から6のいずれか一項に記載の経口製剤。
- 単位投与される、請求項1から7のいずれか一項に記載の経口製剤。
- 前記ビタミンDの14-エピ-アナログが0.5〜20mg含まれる、請求項1から8のいずれか一項に記載の経口製剤。
- 錠剤、ピル、粉剤、ハードカプセル、パステル剤、トローチ、ロゼンジの形態である、請求項1から9のいずれか一項に記載の経口製剤。
- 結合剤、希釈剤、崩壊剤、潤滑剤、流動促進剤、抗酸化剤、甘味剤または香料をさらに含む、請求項1から10のいずれか一項に記載の経口製剤。
- くる病、骨粗しょう症、骨軟化症、乾癬、多発性硬化症もしくはI型糖尿病などの自己免疫疾患、副甲状腺亢進症、良性前立腺肥大、任意のタイプの癌またはビタミンD関連疾患の予防および/または治療に使用するための、請求項1から11のいずれか一項に記載の経口製剤。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10305783A EP2407152A1 (en) | 2010-07-15 | 2010-07-15 | Formulations of 14-epi-analogues of vitamin D |
EP10305783.2 | 2010-07-15 | ||
US12/836,974 US20120015913A1 (en) | 2010-07-15 | 2010-07-15 | Formulations of 14-EPI-Analogues of Vitamin D |
US12/836,974 | 2010-07-15 | ||
PCT/EP2011/061973 WO2012007512A1 (en) | 2010-07-15 | 2011-07-13 | New formulations of 14 - epi -analogues of vitamin d |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2013531023A true JP2013531023A (ja) | 2013-08-01 |
JP5836372B2 JP5836372B2 (ja) | 2015-12-24 |
Family
ID=44281019
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013519093A Expired - Fee Related JP5836372B2 (ja) | 2010-07-15 | 2011-07-13 | ビタミンdの14−エピ−アナログの新しい製剤 |
JP2013519097A Expired - Fee Related JP5836373B2 (ja) | 2010-07-15 | 2011-07-13 | ビタミンdの14−エピ−アナログの新しい製剤 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013519097A Expired - Fee Related JP5836373B2 (ja) | 2010-07-15 | 2011-07-13 | ビタミンdの14−エピ−アナログの新しい製剤 |
Country Status (18)
Country | Link |
---|---|
EP (2) | EP2407154B1 (ja) |
JP (2) | JP5836372B2 (ja) |
KR (2) | KR101821441B1 (ja) |
CN (2) | CN103096876A (ja) |
AU (2) | AU2011278346B2 (ja) |
BR (2) | BR112013000930A2 (ja) |
CA (2) | CA2805198C (ja) |
DK (2) | DK2407155T3 (ja) |
ES (2) | ES2401715T3 (ja) |
HR (2) | HRP20130093T1 (ja) |
IL (2) | IL224192A (ja) |
MX (1) | MX2013000539A (ja) |
NZ (2) | NZ606679A (ja) |
PL (2) | PL2407154T3 (ja) |
PT (2) | PT2407155E (ja) |
SG (2) | SG187072A1 (ja) |
SI (2) | SI2407154T1 (ja) |
WO (3) | WO2012007512A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013531024A (ja) * | 2010-07-15 | 2013-08-01 | ヒブリジェニクス・エスアー | ビタミンdの14−エピ−アナログの新しい製剤 |
US9314474B2 (en) | 2010-07-15 | 2016-04-19 | Hybrigenics, Sa | Formulations of 14-epi-analogues of vitamin D |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014063105A1 (en) * | 2012-10-19 | 2014-04-24 | Celus Pharmaceuticals, Inc. | Vitamin d analogues for the treatment of a neurological disorder |
SG11201810580PA (en) * | 2016-06-08 | 2018-12-28 | Sunregen Healthcare Ag | Lipids with odd number of carbon atoms and their use as pharmaceutical composition or nutritional supplement |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH09500117A (ja) * | 1993-07-09 | 1997-01-07 | ラボラトワル・セラメックス・ソシエテ・アノニム | 新規ビタミンd構造類似体 |
JP2010111593A (ja) * | 2008-11-04 | 2010-05-20 | Teijin Pharma Ltd | 14−エピ−19−ノルプレビタミンd3誘導体 |
JP2013531024A (ja) * | 2010-07-15 | 2013-08-01 | ヒブリジェニクス・エスアー | ビタミンdの14−エピ−アナログの新しい製剤 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10111593A (ja) * | 1996-10-04 | 1998-04-28 | Asahi Optical Co Ltd | 複写機の変倍光学装置 |
US5936105A (en) | 1997-06-13 | 1999-08-10 | Tetrionics, Inc. | 14-EPI-19-nor-vitamin D compounds and methods |
US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US6309663B1 (en) * | 1999-08-17 | 2001-10-30 | Lipocine Inc. | Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents |
GB0305332D0 (en) | 2003-03-10 | 2003-04-09 | Leuven K U Res & Dev | Biological evaluation of novel vitamin D analogues |
US20050020546A1 (en) * | 2003-06-11 | 2005-01-27 | Novacea, Inc. | Pharmaceutical compositions comprising active vitamin D compounds |
SG110107A1 (en) | 2003-09-24 | 2005-04-28 | Bioxell Spa | Compound and use in treatment |
GB0423091D0 (en) * | 2004-10-19 | 2004-11-17 | Leuven K U Res & Dev | Bioactive vitamin d analogues |
US20070093458A1 (en) * | 2005-07-18 | 2007-04-26 | Anchel Schwartz | Preparation of paricalcitol and crystalline forms thereof |
US20080145411A1 (en) * | 2006-10-06 | 2008-06-19 | Kaneka Corporation | Composition of high absorbability for oral administration comprising oxidized coenzyme q10 |
CN102448466A (zh) * | 2009-05-20 | 2012-05-09 | 混合基因股份公司 | 伊奈骨化醇的新治疗应用 |
-
2011
- 2011-07-13 KR KR1020137003060A patent/KR101821441B1/ko active IP Right Grant
- 2011-07-13 SG SG2013002910A patent/SG187072A1/en unknown
- 2011-07-13 ES ES11173860T patent/ES2401715T3/es active Active
- 2011-07-13 DK DK11173860.5T patent/DK2407155T3/da active
- 2011-07-13 SG SG2013002902A patent/SG187071A1/en unknown
- 2011-07-13 MX MX2013000539A patent/MX2013000539A/es active IP Right Grant
- 2011-07-13 AU AU2011278346A patent/AU2011278346B2/en not_active Ceased
- 2011-07-13 PT PT111738605T patent/PT2407155E/pt unknown
- 2011-07-13 KR KR1020137003059A patent/KR101821440B1/ko active IP Right Grant
- 2011-07-13 CA CA2805198A patent/CA2805198C/en not_active Expired - Fee Related
- 2011-07-13 PL PL11173836T patent/PL2407154T3/pl unknown
- 2011-07-13 NZ NZ606679A patent/NZ606679A/en not_active IP Right Cessation
- 2011-07-13 PL PL11173860T patent/PL2407155T3/pl unknown
- 2011-07-13 BR BR112013000930A patent/BR112013000930A2/pt not_active Application Discontinuation
- 2011-07-13 CN CN2011800432762A patent/CN103096876A/zh active Pending
- 2011-07-13 WO PCT/EP2011/061973 patent/WO2012007512A1/en active Application Filing
- 2011-07-13 SI SI201130012T patent/SI2407154T1/sl unknown
- 2011-07-13 CN CN201180043277.7A patent/CN103096877B/zh not_active Expired - Fee Related
- 2011-07-13 BR BR112013000941A patent/BR112013000941A2/pt not_active Application Discontinuation
- 2011-07-13 JP JP2013519093A patent/JP5836372B2/ja not_active Expired - Fee Related
- 2011-07-13 NZ NZ606678A patent/NZ606678A/en not_active IP Right Cessation
- 2011-07-13 ES ES11173836T patent/ES2398640T3/es active Active
- 2011-07-13 AU AU2011278352A patent/AU2011278352B2/en not_active Ceased
- 2011-07-13 CA CA2805203A patent/CA2805203A1/en not_active Abandoned
- 2011-07-13 EP EP11173836A patent/EP2407154B1/en not_active Not-in-force
- 2011-07-13 EP EP11173860A patent/EP2407155B1/en not_active Not-in-force
- 2011-07-13 DK DK11173836.5T patent/DK2407154T3/da active
- 2011-07-13 PT PT111738365T patent/PT2407154E/pt unknown
- 2011-07-13 JP JP2013519097A patent/JP5836373B2/ja not_active Expired - Fee Related
- 2011-07-13 WO PCT/EP2011/061984 patent/WO2012007517A1/en active Application Filing
- 2011-07-13 SI SI201130021T patent/SI2407155T1/sl unknown
- 2011-07-15 WO PCT/EP2011/062127 patent/WO2012007570A2/en active Application Filing
-
2013
- 2013-01-13 IL IL224192A patent/IL224192A/en active IP Right Grant
- 2013-01-13 IL IL224191A patent/IL224191A/en active IP Right Grant
- 2013-02-04 HR HRP20130093AT patent/HRP20130093T1/hr unknown
- 2013-03-19 HR HRP20130237AT patent/HRP20130237T1/hr unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH09500117A (ja) * | 1993-07-09 | 1997-01-07 | ラボラトワル・セラメックス・ソシエテ・アノニム | 新規ビタミンd構造類似体 |
JP2010111593A (ja) * | 2008-11-04 | 2010-05-20 | Teijin Pharma Ltd | 14−エピ−19−ノルプレビタミンd3誘導体 |
JP2013531024A (ja) * | 2010-07-15 | 2013-08-01 | ヒブリジェニクス・エスアー | ビタミンdの14−エピ−アナログの新しい製剤 |
Non-Patent Citations (2)
Title |
---|
JPN6015019940; 実用医薬品添加物, 1974, p.103-120 * |
JPN6015019942; 医薬品添加物事典 2007, 2007, p.67 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013531024A (ja) * | 2010-07-15 | 2013-08-01 | ヒブリジェニクス・エスアー | ビタミンdの14−エピ−アナログの新しい製剤 |
US9314474B2 (en) | 2010-07-15 | 2016-04-19 | Hybrigenics, Sa | Formulations of 14-epi-analogues of vitamin D |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8722664B2 (en) | Spontaneously dispersible N-benzoyl staurosporine compositions | |
UA120508C2 (uk) | Комплекси сиролімусу і його похідних, спосіб їх отримання і фармацевтичні композиції, що містять зазначені комплекси | |
JP2009519343A (ja) | エンテロスタチンの非吸湿性組成物 | |
JP5836372B2 (ja) | ビタミンdの14−エピ−アナログの新しい製剤 | |
US9314474B2 (en) | Formulations of 14-epi-analogues of vitamin D | |
KR20200052280A (ko) | 약학 조성물 | |
MXPA06006926A (es) | Preconcentrado en microemulsion comprendiendo un inhibidor de renina. | |
RU2575819C2 (ru) | Новые составы 14-эпи-аналогов витамина d | |
RU2575792C2 (ru) | Составы 14-эпи-аналогов витамина d | |
EP2407152A1 (en) | Formulations of 14-epi-analogues of vitamin D | |
AU3043400A (en) | Cyclosporin solution | |
WO2024033521A1 (en) | Oral solid dosage forms comprising cannabinoids | |
CN114344309A (zh) | 一种别孕烷醇酮衍生物自乳化制剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130318 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20140701 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150525 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150714 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20151005 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20151102 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5836372 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |